Based on research at Stanford, Bluestar Genomics is working on a non-invasive test for pancreatic cancer.

Bluestar Genomics, a US-based cancer diagnostics technology developer spun out of Stanford University, raised $70m in a series C round led by Mattias Westman, founding partner of asset management firm Prosperity Capital Management. Medical diagnostics group Pathology Asia Holdings also participated in the round, as did an undisclosed venture capital fund and an unnamed asset…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.